[Federal Register Volume 68, Number 103 (Thursday, May 29, 2003)]
[Notices]
[Pages 32089-32090]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-13314]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances, Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under section 1002(a) authorizing the importation of such 
a substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on January 28, 
2003, Roche Diagnostics Corporation, 9115 Hague Road, Indianapolis, 
Indiana 46250, made application by renewal to the Drug Enforcement 
Administration to be registered as an importer of Schedules I & II, for 
the basic classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........  I
Tetrahydrocannabinol (7370)................  I
Alphamethadol (9605).......................  I
Phencyclidine (7471).......................  II
Benzoylecogonine (9180)....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The firm plans to import the listed controlled substances to 
manufacture diagnostic products for distribution to its customers.
    Any manufacturer holding, or applying for, registration as a bulk

[[Page 32090]]

manufacturer of any of these basic classes of controlled substances may 
file written comments on or objections to the application described 
above and may, at the same time, file a written request for a hearing 
on such application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than June 30, 2003.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 301.34(b), (c), (d), 
(e), and (f).
    As noted in a previous notice at 40 FR 43745-46 (September 23, 
1975), all applicants for registration to import basic class of any 
controlled substance in Schedule I or II are and will continue to be 
required to demonstrate to the Deputy Assistant Administrator, Office 
of Diversion Control, Drug Enforcement Administration that the 
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 
U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are 
satisfied.

    Dated: May 2, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-13314 Filed 5-28-03; 8:45 am]
BILLING CODE 4410-09-M